4.57
Schlusskurs vom Vortag:
$5.14
Offen:
$5.14
24-Stunden-Volumen:
188.44K
Relative Volume:
0.80
Marktkapitalisierung:
$42.78M
Einnahmen:
$24.99M
Nettoeinkommen (Verlust:
$-108.83M
KGV:
-0.3041
EPS:
-15.0286
Netto-Cashflow:
$-91.62M
1W Leistung:
-18.54%
1M Leistung:
-49.50%
6M Leistung:
-43.23%
1J Leistung:
-72.54%
Adicet Bio Inc Stock (ACET) Company Profile
Firmenname
Adicet Bio Inc
Sektor
Branche
Telefon
617-482-2333
Adresse
131 DARTMOUTH STREET, BOSTON
Compare ACET vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ACET
Adicet Bio Inc
|
4.57 | 42.78M | 24.99M | -108.83M | -91.62M | -15.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-05 | Fortgesetzt | Jefferies | Buy |
| 2024-09-30 | Fortgesetzt | Guggenheim | Buy |
| 2024-09-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-06-27 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-03-31 | Eingeleitet | SMBC Nikko | Outperform |
| 2022-03-08 | Eingeleitet | Truist | Buy |
| 2022-03-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2021-04-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-04-08 | Eingeleitet | Guggenheim | Buy |
| 2020-11-04 | Eingeleitet | B. Riley Securities | Buy |
| 2020-10-27 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-16 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Adicet Bio Inc Aktie (ACET) Neueste Nachrichten
A new hire waits a year to gain the right to buy Adicet shares - Stock Titan
Every patient in Adicet's lupus study stopped immune-suppressing drugs - Stock Titan
Adicet Bio (Nasdaq:ACET)Stock Analysis - Simply Wall Street
Adicet Bio (NasdaqCM:ACET) Stock Forecast & Analyst Predictions - Simply Wall Street
At $10.99 a share, Gossamer Bio (GOSS) director Sandra Milligan receives a stock option. - Stock Titan
Gossamer Bio grants director options on 10,000 shares - Stock Titan
Devpratim Chakraborty, Brigit SVP, reported no direct Upbound Group (UPBD) shares as of September 22. - Stock Titan
[Form 3] Electra Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Red Robin Gourmet Burgers, Inc.Common Stock (NQ: RRGB - The Chronicle-Journal
Adicet Bio, Inc. (NASDAQ:ACET) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adicet Bio (NASDAQ:ACET) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - marketbeat.com
Stock option sale planned at ScanSource (NASDAQ: SCSC) for 2026 - Stock Titan
Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress - TipRanks
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
Adicet Bio Stock Price Forecast. Should You Buy ACET? - StockInvest.us
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? - Yahoo Finance
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Upgraded to Strong-Buy at Jefferies Financial Group - marketbeat.com
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC and Prepares Prula-Cel Data Release - Kalkine Media
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC, Prula-cel Data Expected in September 2026 - Kalkine Media
Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat
Adicet Bio advances CAR-T programs and clinical pipeline - grafa.com
Adicet Bio completes prula-cel Phase 1 SLE analysis - TipRanks
Adicet Bio says prula-cel last patient visit complete; topline data due Sept 2026, ADI-212 IND cleared - TradingView
The final patient visit is complete in a lupus cell-therapy study. Adicet Bio expects results from 22 patients in September. - stocktitan.net
Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street Zen - marketbeat.com
Press Release Service: Adicet Bio Announces FDA Clearance of IND Application for ADI-212 - CRISPR Medicine News
Adicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancer - marketscreener.com
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com Canada
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com India
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com UK
Adicet Bio receives FDA clearance for prostate cancer trial - investing.com
FDA clears Adicet Bio's application to study a gene-edited prostate cancer therapy - Stock Titan
Here's Why You Should Add ACET Stock to Your Portfolio Now - Yahoo Finance
Adicet (ACET) Trading: Adds 0.32% to Close at $9.41 in the Current Update; Key Range - vinanet.vn
ETFs Investing in Adicet Bio Inc Stocks - TradingView
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Eastern Progress
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
ACET Q2 2026 Earnings: Narrower-Than-Expected Loss of $1.99 Per Share Buoys SharesSegment Revenue Breakdown - vinanet.vn
RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker - Stock Titan
Adicet Bio (ACET) - Zacks Investment Research
Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET) - Seeking Alpha
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Zacks Investment Research
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Yahoo Finance
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsETF Flow - Vinanet
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsVanna Flow - dars.gov.et
Finanzdaten der Adicet Bio Inc-Aktie (ACET)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adicet Bio Inc-Aktie (ACET) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| OrbiMed Genesis Master Fund, L | Shareholder |
Apr 09 '26 |
Proposed Sale |
6.55 |
78,499 |
514,168 |
0 |
| OrbiMed Israel Partners II, L. | Shareholder |
Apr 08 '26 |
Proposed Sale |
6.55 |
40,416 |
264,725 |
0 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 08 '26 |
Sale |
6.42 |
72,939 |
468,082 |
0 |
| OrbiMed Israel Partners Limite | Shareholder |
Apr 07 '26 |
Proposed Sale |
6.43 |
64,242 |
413,076 |
0 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 07 '26 |
Sale |
6.52 |
31,719 |
206,765 |
32,523 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 19 '26 |
Buy |
7.21 |
74,268 |
535,472 |
1,107,873 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 18 '26 |
Buy |
7.04 |
74,577 |
525,022 |
1,033,605 |
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 08 '25 |
Buy |
1.00 |
5,000,000 |
5,000,000 |
9,026,359 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):